SAMUEL WADSWORTH, PH.D.

Corporate Board Profile

Tech Score: 25/100

← Back to All Directors

Software Technology Evidence

1 mention(s) identify SAMUEL WADSWORTH, PH.D. as having software/technology expertise.

Company Filing Date Evidence Reason
PRECISION BIOSCIENCES INC 2024-04-25 Dr. Wadsworth has authored over 80 peer-reviewed papers including some of the earliest published work on adeno-associated viral (“AAV”) vectors for gene therapies and owns over a dozen patents related to AAV vectors for gene therapies. Dr. Wadsworth’s academic credentials include a Ph.D. from the University of Chicago. Dr. Wadsworth has authored over 80 peer-reviewed papers including early work on AAV vectors for gene therapies, owns patents related to gene therapies, and has a Ph.D. He has significant scientific and technical expertise in biotechnology, which involves advanced technical skills likely including programming or related technical knowledge.

PRECISION BIOSCIENCES INC

Filing Date Source Excerpt
2022-03-29 Dr. Wadsworth has authored over 80 peer-reviewed papers including some of the earliest published work on adeno-associated viral vectors for gene therapies and owns over a dozen patents related to AAV vectors for gene therapies. He has a Ph.D. from the University of Chicago.
2023-03-23 Samuel Wadsworth, Ph.D., has served on our Board of Directors since November 2021. Dr. Wadsworth has authored over 80 peer-reviewed papers including some of the earliest published work on adeno-associated viral vectors for gene therapies... Dr. Wadsworth’s academic credentials include a Ph.D. from the University of Chicago and a B.A. from Southern Illinois University.
2023-12-04 Samuel Wadsworth, Ph.D.(11) Consists of 196,933 shares of common stock underlying options exercisable within 60 days of November 15, 2023.
2024-04-25 Dr. Wadsworth has authored over 80 peer-reviewed papers including some of the earliest published work on adeno-associated viral (“AAV”) vectors for gene therapies and owns over a dozen patents related to AAV vectors for gene therapies. Dr. Wadsworth’s academic credentials include a Ph.D. from the University of Chicago.

Data sourced from SEC filings. Last updated: 2026-03-09